Related Experiment Video
Updated: May 26, 2025
13:35
Endoscopic Bilateral Nipple-sparing Mastectomy via a Single Axillary Incision with Immediate Pre-pectoral Implant-based Breast Reconstruction
Published on: May 17, 2024
2.4K
Bilateral Breast Cancer.
1Division of Breast and Endocrine Surgery, Department of Surgery, Nihon University School of Medicine.
The American Surgeon
|February 21, 2025
Summary
Bilateral breast cancer (BBC), including synchronous (SBBC) and metachronous (MBBC), presents distinct risk factors and prognoses. Understanding these differences is crucial for improving patient outcomes and treatment strategies for BBC.
Area of Science:
- Oncology
- Genetics
- Epidemiology
Background:
- Bilateral breast cancer (BBC) encompasses synchronous (SBBC) and metachronous (MBBC) diagnoses.
- These conditions represent a significant percentage of all breast cancer cases.
- Risk factors and prognoses differ between SBBC and MBBC.
Purpose of the Study:
- To review and clarify the distinct characteristics of SBBC and MBBC.
- To identify and compare risk factors associated with each type of BBC.
- To elucidate the prognostic implications of SBBC and MBBC relative to unilateral breast cancer (UBC).
Main Methods:
- Literature review of existing studies on bilateral breast cancer.
- Analysis of epidemiological data regarding incidence rates.
- Comparison of risk factors and survival outcomes based on patient age, histology, and genetic factors.
Main Results:
- SBBC risk factors include older age and lobular histology.
- MBBC risk factors include younger age, lobular histology, and genetic factors.
- Prognosis for SBBC is generally worse than for UBC; MBBC prognosis remains unclear.
Conclusions:
- SBBC and MBBC exhibit different risk factor profiles.
- Further research is needed to clarify MBBC prognosis and the impact of patient-specific factors.
- Distinguishing between SBBC and MBBC is essential for advancing the understanding and management of bilateral breast cancer.
Related Concept Videos
02:57Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
02:07Tumor Progression
6.2K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.2K
02:50Combination Therapies and Personalized Medicine
4.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.8K